1196531-33-5Relevant articles and documents
The Development of a Dimroth Rearrangement Route to AZD8931
Goundry, William R. F.,Boardman, Kay,Cunningham, Oliver,Evans, Matthew,Jones, Martin F.,Millard, Kirsty,Rozada-Sanchez, Raquel,Sawyer, Yvonne,Siedlecki, Paul,Whitlock, Brian
, p. 336 - 345 (2017)
Recently, the aminoquinazoline motif has been highly prevalent in anticancer pharmaceutical compounds. Synthetic methods are required to make this structure on a multikilo scale and in high purity. The initial route to aminoquinazoline AZD8931 suffered from the formation of late-stage impurities. To avoid these impurities, a new high-yielding Dimroth rearrangement approach to the aminoquinazoline core of AZD8931 was developed. Assessment of route options on a gram scale demonstrated that the Dimroth rearrangement is a viable approach. The processes were then evolved for large-scale production with learning from a kilo campaign and two plant-scale manufactures. Identification of key process impurities offers an insight into the mechanisms of the Dimroth rearrangement as well as the hydrogenation of a key intermediate. The final processes were operated on a 30 kg scale delivering the target AZD8931 in 41% overall yield.
NOVEL SALT-554
-
Page/Page column 16, (2009/12/05)
4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate, pharmaceutical compositions containing the difumarate, the use of the difumarate in the treatment of hyperproliferative disorders such as canc